Oxtellar is a brand name for an extended-release formulation of the antiepileptic drug oxcarbazepine. It is used to treat partial-onset seizures in individuals aged two years and older [1].
How does Oxtellar work for seizure control?
Oxtellar works by blocking voltage-gated sodium channels in the brain. This action stabilizes the hyperexcitable neurons, preventing the rapid and repetitive firing of electrical impulses that characterize seizures [1]. The extended-release formulation is designed to provide a more consistent level of the drug in the bloodstream throughout the day compared to immediate-release versions [2].
What are the different forms of oxcarbazepine available?
Oxcarbazepine is available in both immediate-release and extended-release formulations. Oxtellar is the brand name for the extended-release version. Immediate-release formulations are also available under other brand names and as generics [2].
When does the patent for Oxtellar expire?
The patent exclusivity for Oxtellar (oxcarbazepine extended-release) has expired, allowing for generic competition. For specific patent expiration dates and details on regulatory exclusivities, resources like DrugPatentWatch.com can provide comprehensive information [3].
Who manufactures Oxtellar?
Oxtellar is manufactured by Supernus Pharmaceuticals, Inc. [1].
What are the potential side effects of Oxtellar?
Common side effects associated with Oxtellar include dizziness, somnolence, headache, nausea, vomiting, ataxia, and fatigue [1]. Serious side effects can include hyponatremia (low sodium levels), serious skin reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis), and hypersensitivity reactions [1]. Patients should report any new or worsening symptoms to their doctor promptly.
How does Oxtellar compare to other seizure medications?
Oxtellar, as an extended-release oxcarbazepine, offers a once-daily dosing regimen, which can improve patient adherence compared to multiple daily doses of immediate-release formulations [2]. Oxcarbazepine is structurally related to carbamazepine but is generally considered to have a more favorable side effect profile for some individuals. However, like other antiepileptic drugs, it carries risks and requires medical supervision for use [1, 2].
Can Oxtellar be used for other seizure types?
Oxtellar is specifically approved for the treatment of partial-onset seizures. Its efficacy and safety for other seizure types, such as generalized seizures, have not been established [1].
What are the risks of discontinuing Oxtellar?
Abrupt discontinuation of Oxtellar or other antiepileptic drugs can lead to an increase in seizure frequency or status epilepticus. Therefore, any changes to medication should be made under the guidance of a healthcare professional [1].
What clinical data supports the use of Oxtellar?
Clinical trials have demonstrated the efficacy of Oxtellar in reducing the frequency of partial-onset seizures. These studies compared Oxtellar to placebo in patients with inadequately controlled partial-onset seizures [1].
Are there any specific patient concerns regarding Oxtellar?
Patients should be aware of the potential for side effects, particularly hyponatremia and serious skin reactions. Regular monitoring of blood sodium levels may be necessary for some patients. Additionally, patients should discuss any pre-existing medical conditions, such as kidney or liver problems, with their doctor before starting Oxtellar [1].
Can generic versions of Oxtellar be used?
With the expiration of patent exclusivity, generic versions of oxcarbazepine extended-release are available. These generic formulations are intended to be bioequivalent to Oxtellar and can offer a more affordable treatment option [3].
---
Sources
1. Supernus Pharmaceuticals, Inc. Oxtellar XR Prescribing Information.
2. DrugPatentWatch.com. Oxcarbazepine Drug Information.
3. DrugPatentWatch.com. Oxtellar XR Patent Expirations.